Literature DB >> 7835800

Characteristics relating to ovarian cancer risk: implications for prevention and detection.

A S Whittemore1.   

Abstract

Approximately 20,000 women are diagnosed with ovarian cancer in the United States each year, and some 12,000 women die because of it. Epithelial ovarian cancer, the most common histopathologic type, is uncommon before age 40 years, after which incidence rates increase steeply until age 70-79 years and then decrease somewhat. In the United States, the lifetime risk from birth to age 85 years is about 1.5%. There is general agreement that residence in North America or northern Europe, nulliparity, and having a mother or sister with ovarian cancer are associated with an elevated risk, and that increasing number of pregnancies (whether or not full term), increasing length of oral contraceptive use, and increasing duration of lactation are protective. A history of breast or endometrial cancer appears to be associated with a slight elevation in risk. Apart from oral contraceptive use, none of these characteristics can be modified easily to reduce ovarian cancer risk. However, long-term oral contraceptive use before the menopause could prevent as much as half of all ovarian cancer. At present, the subgroup of the population at highest risk consists of women with a mother or sister with the disease; the lifetime ovarian cancer risk in these women is about 9%. A small fraction of them have families with multiple cases of ovarian cancer and early-onset breast cancer, due largely or entirely to mutated alleles of the gene BRCA1. These women, who have a lifetime risk of breast or ovarian cancer of 85-100%, need aggressive screening and possibly prophylactic surgery.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7835800     DOI: 10.1006/gyno.1994.1334

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  13 in total

1.  Recent progress in the diagnosis and treatment of ovarian cancer.

Authors:  Danijela Jelovac; Deborah K Armstrong
Journal:  CA Cancer J Clin       Date:  2011-04-26       Impact factor: 508.702

2.  Nodal status--its impact on prognosis in advanced ovarian cancer.

Authors:  C Bachmann; S Bachmann; T Fehm; A Staebler; S Becker; R Rothmund; C Gardanis; E M Grischke; D Wallwiener; E F Solomayer
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-22       Impact factor: 4.553

3.  Improved survival in BRCA2 carriers with ovarian cancer.

Authors:  Tuya Pal; Jenny Permuth-Wey; Rachna Kapoor; Alan Cantor; Rebecca Sutphen
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

Review 4.  Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies.

Authors:  Leo J Schouten; Christine Rivera; David J Hunter; Donna Spiegelman; Hans-Olov Adami; Alan Arslan; W Lawrence Beeson; Piet A van den Brandt; Julie E Buring; Aaron R Folsom; Gary E Fraser; Jo L Freudenheim; R Alexandra Goldbohm; Susan E Hankinson; James V Lacey; Michael Leitzmann; Annekatrin Lukanova; James R Marshall; Anthony B Miller; Alpa V Patel; Carmen Rodriguez; Thomas E Rohan; Julie A Ross; Alicja Wolk; Shumin M Zhang; Stephanie A Smith-Warner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-04-01       Impact factor: 4.254

5.  Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the ovarian cancer association consortium.

Authors:  Sharon E Johnatty; Jonathan Beesley; Xiaoqing Chen; Amanda B Spurdle; Anna Defazio; Penelope M Webb; Ellen L Goode; David N Rider; Robert A Vierkant; Stephanie Anderson; Anna H Wu; Malcolm Pike; David Van Den Berg; Kirsten Moysich; Roberta Ness; Jennifer Doherty; Mary-Anne Rossing; Celeste Leigh Pearce; Georgia Chenevix-Trench
Journal:  Twin Res Hum Genet       Date:  2009-06       Impact factor: 1.587

6.  Sox2 gene amplification significantly impacts overall survival in serous epithelial ovarian cancer.

Authors:  Jimmy Belotte; Nicole M Fletcher; Mitchell Alexis; Robert T Morris; Adnan R Munkarah; Michael P Diamond; Ghassan M Saed
Journal:  Reprod Sci       Date:  2014-07-18       Impact factor: 3.060

Review 7.  A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer.

Authors:  Tuya Pal; Jenny Permuth-Wey; Thomas A Sellers
Journal:  Cancer       Date:  2008-08-15       Impact factor: 6.860

8.  A possible link between the pubertal growth of girls and ovarian cancer in their daughters.

Authors:  David J P Barker; Clive Osmond; Kent L Thornburg; Eero Kajantie; Johan G Eriksson
Journal:  Am J Hum Biol       Date:  2008 Nov-Dec       Impact factor: 1.937

9.  Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot".

Authors:  Sharon E Johnatty; Jonathan Beesley; Xiaoqing Chen; Stuart Macgregor; David L Duffy; Amanda B Spurdle; Anna deFazio; Natalie Gava; Penelope M Webb; Mary Anne Rossing; Jennifer Anne Doherty; Marc T Goodman; Galina Lurie; Pamela J Thompson; Lynne R Wilkens; Roberta B Ness; Kirsten B Moysich; Jenny Chang-Claude; Shan Wang-Gohrke; Daniel W Cramer; Kathryn L Terry; Susan E Hankinson; Shelley S Tworoger; Montserrat Garcia-Closas; Hannah Yang; Jolanta Lissowska; Stephen J Chanock; Paul D Pharoah; Honglin Song; Alice S Whitemore; Celeste L Pearce; Daniel O Stram; Anna H Wu; Malcolm C Pike; Simon A Gayther; Susan J Ramus; Usha Menon; Aleksandra Gentry-Maharaj; Hoda Anton-Culver; Argyrios Ziogas; Estrid Hogdall; Susanne K Kjaer; Claus Hogdall; Andrew Berchuck; Joellen M Schildkraut; Edwin S Iversen; Patricia G Moorman; Catherine M Phelan; Thomas A Sellers; Julie M Cunningham; Robert A Vierkant; David N Rider; Ellen L Goode; Izhak Haviv; Georgia Chenevix-Trench
Journal:  PLoS Genet       Date:  2010-07-08       Impact factor: 5.917

10.  Potential markers for detection and monitoring of ovarian cancer.

Authors:  Brandon J D Rein; Sajal Gupta; Rima Dada; Joelle Safi; Chad Michener; Ashok Agarwal
Journal:  J Oncol       Date:  2011-04-11       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.